• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CollabRx launches clinical cancer sequencing commercial service

CollabRx launches clinical cancer sequencing commercial service

August 12, 2013
CenterWatch Staff

CollabRx, a data analytics company focused on informing clinical decision making in molecular medicine, has launched the Genetic Variant Annotation (GVA) service. The service is a new product and the company's first offering for the clinical laboratory market. CollabRx will provide GVA to the molecular diagnostic segment of the clinical laboratory market, which includes reference laboratories, hospital laboratories, research institutions and laboratories within academic medical centers.

The service provides for a fully automated and scalable medical informatics solution that pairs the results of genetic sequencing tests with clinically actionable and updated knowledge that can be used to inform patient treatment planning, including the clinical impact of specific genetic profiles and associated therapeutic strategies such as drugs and clinical trials. This content leverages the company's semantic integration platform, a proprietary technology that enables CollabRx scientists and physicians to update the company's knowledge base with the latest medical and scientific data available in the public domain. This knowledge is further contextualized in collaboration with CollabRx's network of over 75 clinical practitioners in the U.S. and Europe. 

GVA initially will be available in oncology to support the clinical interpretation of tests to elucidate tumor mutation profiles generated on any testing platform, including next generation sequencing devices. The range of tumor genetic aberrations interpreted by the GVA service include single base pair substitutions, nucleotide insertions and deletions, frameshifts, gene fusions, large-scale chromosomal rearrangement and copy number variation. Planned functional extensions of the service under development include the interpretation of similar genetic tests for inherited/developmental delay conditions, prenatal screening and neurological and metabolic diseases.

CollabRx will provide GVA using a combination subscription-based and Software as a Service (SaaS) model. 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing